Veradermics
MANE | NYSE
$133.42
-$6.27 (-4.49%)
Nov 2, 2026, 12:01 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 |
|---|---|---|---|
Revenue | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a |
Operating Income | -72.35M | -26.78M | -17.32M |
Interest Income | 1.56M | 481K | 870K |
Pretax Income | -70M | -26.49M | -16.49M |
Net Income | -70M | -26.49M | -16.49M |
Selling & General & Admin | 10.28M | 3.5M | 2.35M |
Research & Development | 62.07M | 23.28M | 14.97M |
Other Expenses | n/a | n/a | n/a |
Operating Expenses | 72.35M | 26.78M | 17.32M |
Interest Expense | n/a | 585K | 36K |
Selling & Marketing Expenses | n/a | n/a | n/a |
Cost & Expenses | 72.35M | 26.78M | 17.32M |
Income Tax Expense | n/a | n/a | n/a |
Shares Outstanding (Basic) | 35.08M | 201.33M | 201.33M |
Shares Outstanding (Diluted) | 35.08M | 201.33M | 201.33M |
EPS (Basic) | -2.38 | -0.14 | -0.08 |
EPS (Diluted) | -2.38 | -0.14 | -0.08 |
EBITDA | -70M | -25.9M | -16.45M |
EBIT | -70M | -25.9M | -16.45M |
Depreciation & Amortization | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove MANE